| Followers | 1432 |
| Posts | 29830 |
| Boards Moderated | 45 |
| Alias Born | 12/10/2012 |
Friday, September 03, 2021 1:59:34 PM
HOW SWEET that was
GO $IPHA
Recent IPHA News
- Number of Shares and Voting Rights of Innate Pharma as of December 31, 2025 • Business Wire • 01/07/2026 06:00:00 AM
- Nouveau nombre d’actions et de droits de vote d’Innate Pharma au 31 décembre 2025 • Business Wire • 01/07/2026 06:00:00 AM
- Number of Shares and Voting Rights of Innate Pharma as of December 18, 2025 • Business Wire • 12/22/2025 06:00:00 AM
- Nouveau nombre d’actions et de droits de vote d’Innate Pharma au 18 décembre 2025 • Business Wire • 12/22/2025 06:00:00 AM
- Innate Pharma publie son calendrier financier pour 2026 • Business Wire • 12/11/2025 06:00:00 AM
- Innate Pharma Releases Its 2026 Financial Calendar • Business Wire • 12/11/2025 06:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/28/2025 02:07:51 PM
- Number of Shares and Voting Rights of Innate Pharma as of November 27, 2025 • Business Wire • 11/28/2025 06:00:00 AM
- Nouveau nombre d’actions et de droits de vote d’Innate Pharma au 27 novembre 2025 • Business Wire • 11/28/2025 06:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/17/2025 11:02:00 AM
- Innate Pharma to Present at Jefferies Global Healthcare Conference • Business Wire • 11/17/2025 06:00:00 AM
- Innate Pharma présentera lors de la Jefferies Global Healthcare Conference • Business Wire • 11/17/2025 06:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/13/2025 11:02:48 AM
- Innate Pharma Reports Third Quarter 2025 Business Update and Financial Results • Business Wire • 11/13/2025 06:00:00 AM
- Innate Pharma présente l'avancée de son portefeuille et ses résultats financiers du troisième trimestre 2025 • Business Wire • 11/13/2025 06:00:00 AM
- Innate Pharma reçoit l'autorisation de la FDA d'avancer TELLOMAK 3, un essai confirmatoire de Phase 3 évaluant lacutamab dans les lymphomes T cutanés • Business Wire • 11/10/2025 06:00:00 AM
- Innate Pharma Announces FDA Clearance to Proceed With TELLOMAK 3, a Confirmatory Phase 3 Trial of Lacutamab in CTCL • Business Wire • 11/10/2025 06:00:00 AM
- Innate Pharma Announces Conference Call and Webcast for Third Quarter 2025 Results and Business Updates • Business Wire • 11/05/2025 06:00:00 AM
- Innate Pharma organise une conférence téléphonique pour ses résultats financiers et l’avancée de son portefeuille au troisième trimestre 2025 • Business Wire • 11/05/2025 06:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 10/15/2025 10:15:11 AM
- Innate Pharma organise un événement analystes et investisseurs dédié à lacutamab le 28 octobre 2025 • Business Wire • 10/14/2025 05:00:00 AM
- Innate Pharma to Host Analyst and Investor Event on Lacutamab on October 28, 2025 • Business Wire • 10/14/2025 05:00:00 AM
- Innate Pharma présente l’avancée de son portefeuille et ses résultats financiers du premier semestre 2025 • Business Wire • 09/17/2025 05:00:00 AM
- Innate Pharma Reports First Half 2025 Business Update and Financial Results • Business Wire • 09/17/2025 05:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/15/2025 10:00:44 AM
UPDATE: Hydromer, Inc. Announces Expansion Into High-Speed Automated Coating and UV Cure Equipment Manufacturing • HYDI • Feb 10, 2026 10:58 AM
MedWell Ai Executes Letter Of Intent To Create America's First Vertically Integrated Regenerative Wellness Eco-System • MWAI • Feb 10, 2026 8:45 AM
LaFleur Minerals Reports Assay Results Highlighting 2.05 g/t Au over 158.25 metres, Confirming Strong Gold Continuity at Swanson Gold Project • LFLRF • Feb 5, 2026 5:29 AM
DRCR Begins Rollout of New Business Model • DRCR • Feb 4, 2026 12:42 PM
BIO-PATH HOLDINGS ANNOUNCES "BPTH 2.0" STRATEGIC PIVOT ON WORLD CANCER DAY; ENGAGES LEGAL COUNSEL FOR REGULATION A OFFERING • BPTH • Feb 4, 2026 10:00 AM
Branded Legacy, Inc. (OTC: BLEG) Successfully Negotiates Retirement of Four Additional Convertible Notes, Preventing Potential Dilution of Hundreds of Millions of Shares • BLEG • Feb 4, 2026 9:07 AM
